Gera Shweta, Ettel Mark, Acosta-Gonzalez Gabriel, Xu Ruliang
Shweta Gera, Department of Pathology, Montefiore Medical Center, Bronx, NY 10467, United States.
World J Hepatol. 2017 Feb 28;9(6):300-309. doi: 10.4254/wjh.v9.i6.300.
Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities.
肝细胞胆管癌(CHC)是一种预后较差的罕见肿瘤,在所有原发性肝肿瘤中的发病率为1.0%-4.7%。该实体即将更名为肝内胆管癌。已知的肝细胞癌(HCC)危险因素也与CHC有关,包括病毒性肝炎和肝硬化。术前诊断这种肿瘤很困难。肿瘤内主要的组织学成分在很大程度上决定了主要的影像学特征,这使得鉴别诊断变得困难。HCC和胆管癌的异质性和重叠性影像学特征应引起对CHC的怀疑,建议在进行治疗前进行多次(从肿瘤不同区域获取)核心活检。血清肿瘤标志物CA19-9和甲胎蛋白有助于诊断,但在切除前仍是一项具有挑战性的诊断。有足够的数据支持双潜能肝祖细胞作为CHC的起源细胞。目前世界卫生组织的分类根据组织形态学特征将CHC分为两种主要类型:经典型和具有干细胞特征的CHC。肝移植是可用的治疗方式之一,其他治疗选择包括经动脉化疗栓塞、射频消融和经皮乙醇注射。我们发表一篇关于CHC的综述文章,重点介绍其危险因素、起源、组织学分类和治疗方式。